The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
- BBC News: “Rare case of woman’s body ridding itself of HIV”RIO Chief Investigator Prof Sarah Fidler and Protocol Co-Chair Prof John Frater interviewed. 17 November 2021 A woman from Argentina […]
- RIO Patient Representative, Mr Simon Collins, wins biennial EACS AwardSimon Collins was the joint award winner at the 18th European AIDS Conference held on the 27th – 30th October […]
- RIO trial represented at EACS 2021The 18th European AIDS Conference (EACS) took place on the 27th – 30th of October 2021 both in London and […]
- Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
- Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence
- PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial
- Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa
- Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.